Carlo Gambacorti‐Passerini

Active 1986–2025

Also published as
Carlo Gambacorti Passerini
124
Papers
23,252
Citations
77
h-index
120
i10-index

Citations

Citations per year for Carlo Gambacorti‐Passerini1979: 5 citations1988: 1 citations1989: 1 citations1990: 1 citations1992: 1 citations1993: 3 citations1994: 3 citations1995: 8 citations1996: 10 citations1997: 10 citations1998: 25 citations1999: 44 citations2000: 59 citations2001: 91 citations2002: 168 citations2003: 204 citations2004: 130 citations2005: 108 citations2006: 109 citations2007: 115 citations2008: 120 citations2009: 124 citations2010: 121 citations2011: 123 citations2012: 173 citations2013: 188 citations2014: 220 citations2015: 221 citations2016: 267 citations2017: 190 citations2018: 157 citations2019: 572 citations2020: 702 citations2021: 784 citations2022: 557 citations2023: 379 citations2024: 679 citations2025: 244 citations2026: 10 citations1980–1987: no citations, so these years are not shown1991: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,416 citing papers, 25.7% of this breakdownItaly: 784 citing papers, 8.3% of this breakdownGermany: 644 citing papers, 6.8% of this breakdownUnited Kingdom: 636 citing papers, 6.8% of this breakdownChina: 578 citing papers, 6.1% of this breakdownFrance: 487 citing papers, 5.2% of this breakdownCanada: 286 citing papers, 3% of this breakdownSpain: 284 citing papers, 3% of this breakdownAustralia: 268 citing papers, 2.9% of this breakdownJapan: 259 citing papers, 2.8% of this breakdownSwitzerland: 248 citing papers, 2.6% of this breakdownNetherlands: 208 citing papers, 2.2% of this breakdown
0%25.7%Other 24.6%

Fields

  • Medicine66.1%
  • Biochemistry, Genetics and Molecular Biology28.7%
  • Immunology and Microbiology2.4%
  • Computer Science0.6%
  • Chemistry0.4%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • Other1.5%

Topics

  • Chronic Myeloid Leukemia Treatments10.3%
  • Acute Myeloid Leukemia Research7.8%
  • Chronic Lymphocytic Leukemia Research6%
  • Eosinophilic Disorders and Syndromes4.4%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment3.1%
  • Acute Lymphoblastic Leukemia research2.6%
  • Other65.8%

Coauthors

All papers

Open in search
  1. Clinical and biological implications of driver mutations in myelodysplastic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anthony R. Green, Jacqueline Boultwood, Paresh Vyas, Eva Hellström‐Lindberg, David Bowen, Mario Cazzola, Michael R. Stratton, Peter J. Campbell - Blood 2013 cited by 1,832

  2. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 1,124

  3. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2018 cited by 583

  4. SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , E. Joanna Baxter, J Score, Anna Gallì, Matteo Giovanni Della Porta, Erica Travaglino, Michael J. Groves, Sudhir Tauro, Nikhil C. Munshi, Kristina Anderson, Adel K. El‐Naggar, Andrej Fischer, Ville Mustonen, Alan J. Warren, Nicholas C.P. Cross, Anthony R. Green, P. Andrew Futreal, Michael R. Stratton, Peter J. Campbell - New England Journal of Medicine 2011 cited by 1,216

  5. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 493

  6. Integrative pathway enrichment analysis of multivariate omics data

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dale W. Garsed, Mark Gerstein, Gad Getz, Abel González-Pérez, Qianyun Guo, Marta Gut, David Haan, Mark Hamilton, Nicholas J. Haradhvala, Arif Harmanci, Mohamed Helmy, Carl Herrmann, Julian M. Hess, Asger Hobolth, Ermin Hodzic, Chen Hong, Henrik Hornshøj, Keren Isaev, José M. G. Izarzugaza, Rory Johnson, Todd A. Johnson, Malene Juul, Randi Istrup Juul, Andre Kahles, Abdullah Kahraman, Manolis Kellis, Ekta Khurana, Jaegil Kim, Jong K. Kim, Young-Wook Kim, Jan Komorowski, Jan O. Korbel, Sushant Kumar, Andrés Lanzós, Michael S. Lawrence, Shantao Li, Kjong-Van Lehmann, Shantao Li, Xiaotong Li, Ziao Lin, Eric Minwei Liu, Lucas Lochovsky, Shaoke Lou, Tobias Madsen, Kathleen Marchal, Iñigo Martincorena, Alexander Martinez‐Fundichely, Yosef E. Maruvka, Patrick D. McGillivray, William Meyerson, Ferran Muiños, Loris Mularoni, Hidewaki Nakagawa, Morten Muhlig Nielsen, Keunchil Park, Kiejung Park, Jakob Skou Pedersen, Oriol Pich, Tirso Pons, Sergio Pulido-Tamayo, Benjamin J. Raphael, Iker Reyes-Salazar, Matthew A. Reyna, Esther Rheinbay, Mark A. Rubin, Carlota Rubio-Pérez, Radhakrishnan Sabarinathan, S. Cenk Şahinalp, Gordon Saksena, Leonidas Salichos and 1,360 more - Nature Communications 2020 cited by 236

  7. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2022 cited by 126

  8. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

    Authors: , , , , , , , , , , , , , , , , , , , - Leukemia 2022 cited by 141

  9. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - JAMA 2024 cited by 114

  10. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Josep‐María Ribera, Renato Bassan, Marc Delord, Dieter Hoelzer, Hervé Dombret, Oliver G. Ottmann - Blood 2016 cited by 326

  11. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells

    Authors: , , , , , , - Cancer Letters 2002 cited by 530

  12. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option

    Authors: , , , , , - Blood Reviews 2022 cited by 64

  13. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark Gerstein, Gad Getz, Abel González-Pérez, Qianyun Guo, Marta Gut, David Haan, Mark P. Hamilton, Nicholas J. Haradhvala, Arif Harmanci, Mohamed Helmy, Carl Herrmann, Julian M. Hess, Asger Hobolth, Ermin Hodzic, Chen Hong, Henrik Hornshøj, Keren Isaev, José M. G. Izarzugaza, Rory Johnson, Todd A. Johnson, Malene Juul, Randi Istrup Juul, André Kahles, Abdullah Kahraman, Manolis Kellis, Ekta Khurana, Jaegil Kim, Jong K. Kim, Young-Wook Kim, Jan Komorowski, Jan O. Korbel, Sushant Kumar, Andrés Lanzós, Erik G. Larsson, Michael S. Lawrence, Dong-Hoon Lee, Kjong-Van Lehmann, Shantao Li, Xiaotong Li, Ziao Lin, Eric Minwei Liu, Lucas Lochovsky, Shaoke Lou, Tobias Madsen, Kathleen Marchal, Iñigo Martincorena, Alexander Martinez‐Fundichely, Yosef E. Maruvka, Patrick D. McGillivray, William Meyerson, Ferran Muiños, Loris Mularoni, Hidewaki Nakagawa, Morten Muhlig Nielsen, Marta Paczkowska, Keunchil Park, Kiejung Park, Jakob Skou Pedersen, Oriol Pich, Tirso Pons, Sergio Pulido-Tamayo, Benjamin J. Raphael, Jüri Reimand, Iker Reyes-Salazar, Matthew A. Reyna, Esther Rheinbay, Mark A. Rubin, Carlota Rubio-Pérez, Radhakrishnan Sabarinathan, S. Cenk Sahinalp and 1,362 more - Communications Biology 2020 cited by 190

  14. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patrizia Tosi, Francesco Lanza, Massimo Massaia, Mauro Turrini, Felicetto Ferrara, Carmela Gurrieri, Daniele Vallisa, Maurizio Martelli, Enrico Derenzini, Attilio Guarini, Annarita Conconi, Annarosa Cuccaro, Laura Cudillo, Domenico Russo, Fabrizio Ciambelli, Anna Maria Scattolin, Mario Luppi, Carmine Selleri, Elettra Ortu La Barbera, Celestino Ferrandina, Nicola Di Renzo, Attilio Olivieri, Monica Bocchia, Massimo Gentile, Francesco Marchesi, Pellegrino Musto, Augusto B. Federici, Anna Candoni, Adriano Venditti, Carmen Fava, Antonio Pinto, Piero Galieni, Luigi Rigacci, Daniele Armiento, Fabrizio Pane, Margherita Oberti, Patrizia Zappasodi, Carlo Visco, Matteo Franchi, Paolo Grossi, Lorenza Bertù, Giovanni Corrao, Livio Pagano, Paolo Corradini - The Lancet Haematology 2020 cited by 554

  15. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2018 cited by 157

  16. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kevin R. Kelly, P. Le Coutre, Carmen Martínez Chamorro, Vivian G. Oehler, G. Orti Pascual, Andreas Petzer, Ester Pungolino, Giovanna Rege‐Cambrin, Françoise Rigal‐Huguet, Gail J. Roboz, P. Rousselot, Fermín Sánchez‐Guijo, Guillermo Sanz Santillana, Philippe Schafhausen, C. Scheid, Stefan Schmidt, Giorgina Specchia, Juan Luis Steegmann, Leif Stenke - Leukemia 2020 cited by 83

  17. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2002 cited by 2,030

  18. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

    Authors: , , , , , , , , , , , , , , - Blood 2011 cited by 461

  19. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

    Authors: , , , , , , , , , , , - Blood 2012 cited by 318

  20. Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

    Authors: , , , , , , , , , , - Journal of Clinical Oncology 2012 cited by 469

  21. Pathway and network analysis of more than 2500 whole cancer genomes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Keith A. Boroevich, John Busanovich, Peter J. Campbell, Joana Carlevaro-Fita, Dimple Chakravarty, Calvin Wing Yiu Chan, Ken Chen, Jung Kyoon Choi, Jordi Deu-Pons, Klev Diamanti, Lars Feuerbach, J. Lynn Fink, Nuno A. Fonseca, Joan Frigola, Carlo Gambacorti‐Passerini, Dale W. Garsed, Mark Gerstein, Qianyun Guo, Marta Gut, Mark P. Hamilton, Nicholas J. Haradhvala, Arif Harmanci, Mohamed Helmy, Carl Herrmann, Julian M. Hess, Asger Hobolth, Ermin Hodzic, Chen Hong, Henrik Hornshøj, Keren Isaev, Rory Johnson, Todd A. Johnson, Malene Juul, Randi Istrup Juul, André Kahles, Manolis Kellis, Jaegil Kim, Jong K. Kim, Youngwook Kim, Jan Komorowski, Jan O. Korbel, Sushant Kumar, Andrés Lanzós, Erik Larsson, Donghoon Lee, Kjong-Van Lehmann, Shantao Li, Xiaotong Li, Ziao Lin, Eric Minwei Liu, Lucas Lochovsky, Shaoke Lou, Tobias Madsen, Iñigo Martincorena, Alexander Martinez‐Fundichely, Yosef E. Maruvka, Patrick D. McGillivray, William Meyerson, Ferran Muiños, Loris Mularoni, Hidewaki Nakagawa, Morten Muhlig Nielsen, Keunchil Park, Kiejung Park, Tirso Pons, Iker Reyes-Salazar, Esther Rheinbay, Carlota Rubio-Pérez, Gordon Saksena, Leonidas Salichos and 1,354 more - Nature Communications 2020 cited by 115

  22. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2021 cited by 49

  23. Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

    Authors: , , , , , , , , , , , , , , , , , - American Journal of Hematology 2018 cited by 110

  24. Evaluating the performance of large language models in haematopoietic stem cell transplantation decision‐making

    Authors: , , , , , , , , , , , , , , - British Journal of Haematology 2023 cited by 16